Pharmacokinetic modeling of ethyl loflazepate (Victan) and its main active metabolites.
A simultaneous consideration of plasma and urine data of unchanged drug and active metabolites, taking into account the metabolic process of the precursor, is described. The maximum likelihood principle was used to estimate parameters. This methodology is highly efficient in determining the contribution of the two main and active metabolites in the pharmacological response of ethyl loflazepate. It also may serve in the search for optimum dosage regimens in clinical practice.
Ba
B B
BB
INSERM U 278, Faculty of Pharmacy, Marseilles, France.
Iliadis
A
A
Cano
J P
JP
D000284:Administration, Oral; D000465:Algorithms; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001569:Benzodiazepines; D001570:Benzodiazepinones / Q000008:administration & dosage / Q000493:pharmacokinetics*; D001711:Biotransformation; D003198:Computer Simulation; D006801:Humans; D008962:Models, Theoretical
D014151:Anti-Anxiety Agents; D001570:Benzodiazepinones; D001569:Benzodiazepines; C029617:ethyl loflazepate